{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:10:05Z","timestamp":1749636605132,"version":"3.41.0"},"reference-count":25,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15081","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:55:32Z","timestamp":1746791732000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Retroperitoneal growth of high\u2011grade serous ovarian carcinoma: A case report"],"prefix":"10.3892","volume":"30","author":[{"given":"Pengnan","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhou","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"key20250611125728_b1-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20250611125728_b2-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: New opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key20250611125728_b3-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am J Pathol"},{"key":"key20250611125728_b4-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"key20250611125728_b5-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"key20250611125728_b6-ol-30-1-15081","article-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014","edition":"4th edition"},{"key":"key20250611125728_b7-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fonc.2014.00322","article-title":"Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer","volume":"4","author":"Ohman","year":"2014","journal-title":"Front Oncol"},{"author":"National Cancer Institute Surveillance, Epidemiology and End Results Program","key":"key20250611125728_b8-ol-30-1-15081","article-title":"Cancer Stat Facts: Ovarian Cancer"},{"key":"key20250611125728_b9-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1470-2045(11)70333-3","article-title":"Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project","volume":"13","author":"Gilbert","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20250611125728_b10-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"article-title":"Five Things Physicians and Patients Should Question","year":"2013","author":"The American College of Obstetricians and Gynecologists","key":"key20250611125728_b11-ol-30-1-15081"},{"key":"key20250611125728_b12-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20250611125728_b13-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"key20250611125728_b14-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2010.07.025","article-title":"CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study","volume":"119","author":"van Altena","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20250611125728_b15-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"key20250611125728_b16-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"18190","DOI":"10.1038\/s41598-021-97564-1","article-title":"Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer","volume":"11","author":"Piatek","year":"2021","journal-title":"Sci Rep"},{"key":"key20250611125728_b17-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"189224","DOI":"10.1016\/j.bbcan.2024.189224","article-title":"Biomarkers in high grade serous ovarian cancer","volume":"1879","author":"Bates","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20250611125728_b18-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0889-8588(03)00058-3","article-title":"Optimizing primary chemotherapy in ovarian cancer","volume":"17","author":"Markman","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20250611125728_b19-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"key20250611125728_b20-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"key20250611125728_b21-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdt350","article-title":"Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant GeparTrio trial","volume":"24","author":"Denkert","year":"2013","journal-title":"Ann Oncol"},{"key":"key20250611125728_b22-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1038\/srep08924","article-title":"Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: A systematic review and meta-analysis","volume":"5","author":"Qi","year":"2015","journal-title":"Sci Rep"},{"key":"key20250611125728_b23-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/jco.2014.32.15_suppl.3097","article-title":"Phase I\/IIa study of therapeutic p16INK4a vaccination in patients with HPV-associated cancers","volume":"32","author":"Reuschenbach","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20250611125728_b24-ol-30-1-15081","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/carcin\/21.9.1761","article-title":"Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens","volume":"21","author":"Rice","year":"2000","journal-title":"Carcinogenesis"},{"article-title":"Ovarian Cancer, version 1.2023","year":"2023","author":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology","key":"key20250611125728_b25-ol-30-1-15081"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:57:34Z","timestamp":1749635854000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,9]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15081","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}